WO2011008053A3 - Propionate de n,n-diméthyl diamide imidocarbonimidique, son procédé de préparation ainsi que compositions et combinaisons pharmaceutiques le contenant - Google Patents

Propionate de n,n-diméthyl diamide imidocarbonimidique, son procédé de préparation ainsi que compositions et combinaisons pharmaceutiques le contenant Download PDF

Info

Publication number
WO2011008053A3
WO2011008053A3 PCT/KR2010/004673 KR2010004673W WO2011008053A3 WO 2011008053 A3 WO2011008053 A3 WO 2011008053A3 KR 2010004673 W KR2010004673 W KR 2010004673W WO 2011008053 A3 WO2011008053 A3 WO 2011008053A3
Authority
WO
WIPO (PCT)
Prior art keywords
propionate
same
metformin
pharmaceutical compositions
combinations containing
Prior art date
Application number
PCT/KR2010/004673
Other languages
English (en)
Korean (ko)
Other versions
WO2011008053A2 (fr
Inventor
김성욱
전성수
민창희
강민석
김용은
구자성
Original Assignee
한올바이오파마주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한올바이오파마주식회사 filed Critical 한올바이오파마주식회사
Publication of WO2011008053A2 publication Critical patent/WO2011008053A2/fr
Publication of WO2011008053A3 publication Critical patent/WO2011008053A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/122—Propionic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C277/00—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne du propionate de metformine, un procédé de préparation de ce dernier, ainsi que des compositions et des combinaisons pharmaceutiques le contenant. Le propionate de metformine selon la présente invention présente un excellent effet pharmacologique comparé à l'hydrochlorure de metformine et permet d'obtenir un effet thérapeutique par administration d'une quantité inférieure à celle de l'hydrochlorure de metformine. En outre, le propionate de metformine présente d'excellentes propriétés physico-chimiques, telles qu'une solubilité, une stabilité, une hygroscopicité et une propriété de prévention d'adsorption, utilisées pour le traitement de formulations et peut par conséquent être efficacement utilisée en tant que sel pharmaceutiquement acceptable de la metformine.
PCT/KR2010/004673 2009-07-17 2010-07-16 Propionate de n,n-diméthyl diamide imidocarbonimidique, son procédé de préparation ainsi que compositions et combinaisons pharmaceutiques le contenant WO2011008053A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2009-0065244 2009-07-17
KR20090065244 2009-07-17

Publications (2)

Publication Number Publication Date
WO2011008053A2 WO2011008053A2 (fr) 2011-01-20
WO2011008053A3 true WO2011008053A3 (fr) 2011-04-21

Family

ID=43449997

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/004673 WO2011008053A2 (fr) 2009-07-17 2010-07-16 Propionate de n,n-diméthyl diamide imidocarbonimidique, son procédé de préparation ainsi que compositions et combinaisons pharmaceutiques le contenant

Country Status (2)

Country Link
KR (2) KR20110007984A (fr)
WO (1) WO2011008053A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2405566C2 (ru) 2005-02-03 2010-12-10 Дзе Дженерал Хоспитал Корпорейшн Способ лечения рака, устойчивого к гефитинибу
PE20070763A1 (es) 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
MX365008B (es) 2008-06-17 2019-05-20 Wyeth Llc Combinaciones antineoplasticas que contienen hki-272 y vinorelbina.
JP5681108B2 (ja) 2008-08-04 2015-03-04 ワイス・エルエルシー ４−アニリノ−３−シアノキノリンとカペシタビンの抗新生物薬の組合せ
ES2561495T3 (es) 2009-04-06 2016-02-26 Wyeth Llc Régimen de tratamiento que utiliza neratinib contra cáncer de mama
CN107308130B (zh) 2009-11-09 2021-06-15 惠氏有限责任公司 包衣药物球状体及消除或减少病症如呕吐和腹泻的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029314A1 (fr) * 1997-12-08 1999-06-17 Bristol-Myers Squibb Company Sels de metformine et procede
WO1999047128A1 (fr) * 1998-03-19 1999-09-23 Bristol-Myers Squibb Company Systeme d'apport a liberation lente biphasique destine a des medicaments a solubilite elevee et procede associe
KR100760430B1 (ko) * 2004-12-31 2007-10-04 한미약품 주식회사 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
KR20090013736A (ko) * 2007-08-02 2009-02-05 주식회사 한독약품 메트포르민 산 부가염을 포함하는 서방성 제제

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029314A1 (fr) * 1997-12-08 1999-06-17 Bristol-Myers Squibb Company Sels de metformine et procede
WO1999047128A1 (fr) * 1998-03-19 1999-09-23 Bristol-Myers Squibb Company Systeme d'apport a liberation lente biphasique destine a des medicaments a solubilite elevee et procede associe
KR100760430B1 (ko) * 2004-12-31 2007-10-04 한미약품 주식회사 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
KR20090013736A (ko) * 2007-08-02 2009-02-05 주식회사 한독약품 메트포르민 산 부가염을 포함하는 서방성 제제

Also Published As

Publication number Publication date
WO2011008053A2 (fr) 2011-01-20
KR20120031288A (ko) 2012-04-02
KR20110007984A (ko) 2011-01-25

Similar Documents

Publication Publication Date Title
WO2011008054A3 (fr) Sel d'acide butyrique de n,n-diméthyl diamide imidocarbonimidique, son procédé de préparation, ainsi que compositions et combinaisons pharmaceutiques le contenant
WO2011008053A3 (fr) Propionate de n,n-diméthyl diamide imidocarbonimidique, son procédé de préparation ainsi que compositions et combinaisons pharmaceutiques le contenant
WO2012047017A3 (fr) Dérivé 2,3-dihydro-isoindol-1-one et composition le comprenant
MX2015010971A (es) Derivado novedoso de pirazol.
WO2014151871A3 (fr) Inhibiteurs de jak2 et alk2 et leurs procédés d'utilisation
WO2013188792A3 (fr) Stéroïdes neuroactifs, compositions, et leurs utilisations
WO2013179307A3 (fr) Compositions pharmaceutiques stabilisées de saxagliptine
MY149731A (en) Compounds
MY151986A (en) Adamantyl diamide derivatives and uses of same
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
WO2011005811A8 (fr) Polythérapie pour le traitement du diabète
EP3626253A3 (fr) Formulations stables de linaclotide
IL195732A (en) Pharmaceutical compounds containing passoterodine, their use and method for their preparation
WO2007014619A8 (fr) Nouveaux dérivés d’imidazole carboxamide comme inhibiteurs de la fructose-1,6-bisphosphatase, et compositions pharmaceutiques qui les contiennent
TN2013000253A1 (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
WO2010132765A3 (fr) Analogues d'aminoglycoside antibactériens
WO2011012816A3 (fr) Formulation pharmaceutique
WO2010092090A3 (fr) Nouveaux sels de la sitagliptine
WO2011044501A3 (fr) Analogues d'aminoglycoside antibactériens
WO2012048129A3 (fr) Inhibiteurs de kinase de type polo
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
NZ602450A (en) Agomelatine hydrochloride hydrate and preparation thereof
WO2012135615A3 (fr) Enopeptines, utilisations de celles-ci, et procédés de synthèse de celles-ci
WO2012053009A3 (fr) Compositions pharmaceutiques comprenant des agents de décoloration de la peau
WO2010070677A3 (fr) Procédé de préparation de prasugrel et de ses sels pharmaceutiquement acceptables

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10800064

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10800064

Country of ref document: EP

Kind code of ref document: A2